Previous 10 | Next 10 |
Pixabay Genomic regenerative medicines are widely viewed as the next major era in biotechnology. This article follows a review of the pipeline and launched medicines which left the question open of whether the BioMarin ( BMRN ) hemophilia news last week is company-specific or a read to...
BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...
On script, BioMarin Pharmaceutical's ( BMRN -36.2% ) stumble with hemophilia A gene therapy candidate valoctogene roxaparvovec has stoked modest buying in other players in the space as investors perceive improved prospects from the sidelining of a key competitor. More news on: BioMarin P...
Sangamo Therapeutics ( SGMO ) has delivered another impressive “Neuro” partnership with Novartis ( NVS ) on the heels of their monster deal with Biogen ( BIIB ) earlier in the year, explains John McCamant , editor of The Medical Technology Stock Letter — and a pa...
Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August 12, 2020 at 2:55 p.m. Eastern Time. The presentation will be webcast live and may be accessed ...
The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Q2 earnings show Sangamo Therapeutics ( SGMO +3.1% ) revenue of $21.6M vs. $17.5M last year. More news on: Sangamo Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Read more ...
Image source: The Motley Fool. Sangamo Therapeutics Inc (NASDAQ: SGMO) Q2 2020 Earnings Call Aug 5, 2020 , 5:00 p.m. ET Operator Continue reading
Sangamo Therapeutics, Inc. (SGMO) Q2 2020 Earnings Conference Call August 5, 2020 17:00 ET Company Participants McDavid Stilwell - Senior Vice President, Corporate Communication and IR Sandy Macrae - Chief Executive Officer Bettina Cockroft - Chief Medical Officer Sung Lee - Ch...
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
2024-05-15 13:30:05 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for SGMO on May 15, 2024 11:01AM ET. The previous analyst recommendation was Underperform. SGMO was trading at $0.5901 at issue of the analyst recommendation. The overall analyst consensus ...
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrie...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from...